Conversion from parenteral to oral methadone

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 22, Issue 3, 2008, Pages 200-205

  González Barboteo, Jesús ^a   Porta Sales, Josep ^a   Sánchez, Daniel ^b   Tuca, Albert ^a   Gómez Batiste, Xavier ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b 08027 l'Hospitalet de Llobregat ^*

Author keywords

Conversion; Dose; Methadone; Neoplasia; Opioids; Pain; Palliative care

Indexed keywords

METHADONE; MORPHINE; OPIATE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; ARTICLE; BLADDER CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL PRACTICE; COLON CANCER; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; LUNG CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NAUSEA; NEUROPATHIC PAIN; PAIN; PAIN ASSESSMENT; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE CANCER; RETROSPECTIVE STUDY; SOMNOLENCE; TREATMENT OUTCOME; VOMITING; BIOAVAILABILITY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; MALE; METHADONE; MIDDLE AGED; NEOPLASMS; PAIN; PALLIATIVE CARE; RETROSPECTIVE STUDIES;

EID: 60249094652     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.1080/15360280802251199     Document Type: Article

References (29)

1. Hanks GW, de Conno F, Cherny N., et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587-593.
2. Bruera E, Neumann CM. Role of methadone in the management of pain in cancer patients. Oncology (Hunting) 1999;13:1275-1282.
3. Moryl N, Santiago-Palma J, Kornik C, et al. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain 2002;96:325-328.
4. Bruera E, Lynn J, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004;22:185-92.
5. Centeno C, Sánchez R, Vara F. Metadona en el tratamiento del dolor por cáncer: experiencia del Hospital Los Montalvos, Salamanca. Med Pal (Madrid) 2004; 11:157-63.
6. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions, and protocols of administration. Support Care Cancer. 2001;9:73-83.
7. Gagnon C. The use of methadone in the care of the dying. Eur J Palliat Care.1997;4:152-8.
8. Inturrisi CE. Clinical pharmacologyof opioids for pain. Clin J Pain. 2002;18:S3-S13.
9. Gómez-Batiste X, Porta J, Tuca A. Palliative care at the Institut Català d'Oncologia, Barcelona. Eur J Palliat Care.2003; 10(5):202-05
10. Bruera E, MacMillan K, Hanson J, MacDonald RN. The Edmonton staging system for cancer pain: preliminary report. Pain. 1989;37(2):203-209.
11. Porta J, Rodríguez D, Sala C.Dolor. En: Porta J Gómez-Batiste X, Tuca A, ed. Manual de control de síntomas en pacientes con cáncer avanzado y terminal. Madrid: Arán: 33-89.
12. Nelson KA, Glare PA, Walsh D, Groh ES. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage. 1997;13:262-7.
13. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med. 2002; 5:127-38.
14. Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain.J Pain Symptom Manage. 1999; 18:120-5.
15. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain. 1986; 25:297-312.
16. Inturrisi CE, Portenoy RK, Max MB, Colburn WA, Foley KM. Pharmacokinetic- pharmacodynamic relationshipsof methadone infusions in patient with cancer pain. Clin Pharmacol Ther. 1990;47:565-77.
17. Nilson MI, Merescar U, Anggard E. Clinical pharmacokinetics of methadone. Acta Anaesthes Scand. 1982;(supl 74):66-69.
18. Verebely K, Volavka J, Mulé S, Resnick R. Methadone in man:pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther.1975;18:180-190.
19. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadoneinpatients with chronic pain. Clin Pharmacol Ther. 1987;41:392-401.
20. De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol. 1996;14:2836-2842.
21. Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer. 1998;82:1167-1173.
22. Mercadante S, Casuccio A, Agnello A, Barresi L. Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manage. 1999;18:188-192.
23. Mercadante S, Casuccio A, Groff L, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001;19:2898-2904.
24. Santiago-Palma J, Khojainova N, Kornik C, et al. Intravenous methadone in the management of chronic cancer pain. Cancer 2001;92:1919-1925.
25. Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996;67:115-119.
26. Nicholson AB. Methadone for cancer pain. The Cochrane Database of Systematic reviews. 2004, Issue 1. Art No.:CD003971.pub2.DOI:1002/-14651858. CD003971.pub2.
27. Porta-Sales J, Martínez M, Gómez-Batiste X, et al. Descripción de la complejidad de los pacientes en la consulta externa de un Servicio de Cuidados Paliativos en un centro terciario: resultados preliminares. Med Pal (Madrid) 2003;10:20-23.
28. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P4503A4enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996;9:365-373.
29. Kharasch E, Hoffer C, Whittington D Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and meiotic effects of methadone. Clin Pharmacol Ther. 2004;76:250-269.